Prenatal Screening for Spinal Muscular Atrophy too Costly
Topic: Pediatric Health Concerns
Author: Elsevier Health Sciences
Published: 2010/03/08
Contents: Summary - Introduction - Main Item - Related Topics
Synopsis: Is prenatal screening for rare diseases like spinal muscular atrophy too costly.
Introduction
Is prenatal screening for rare diseases like spinal muscular atrophy too costly- New study in the American Journal of Obstetrics & Gynecology explores this controversy.Main Item
Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA. An article which may shed light on this controversy appears in the March 2010 issue of the American Journal of Obstetrics & Gynecology.
Using a decision analytic model, the authors found that 12,500 women need to be screened to prevent one case of SMA, at a cost of $5 million per case averted. They also determined that at $4.9 million per Quality-Adjusted Life Year (QALY), such screening was not cost-effective. Maternal QALY was used to measure the combined effects of caring for a child who suffers from the disease with resultant premature death and disability.
The cost of the procedures involved, maternal and paternal genetic testing, fetal amniocentesis and genetic testing of fetal cells, were all estimated from data published in the literature. The model assumed that couples with a positive fetal test would elect pregnancy termination. Lifetime costs of caring for an affected child were estimated from costs for similar diseases documented in the medical literature. All costs were adjusted to 2009 dollars using the Consumer Price Index.
The authors found that the cost per case averted was the most influenced by the baseline prevalence of disease in the population screened. For those couples with a higher prevalence, such as those with a family history of disease, screening may be a cost-effective strategy.
Writing in the article, Sarah E. Little, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, and co-authors state that "our estimated cost per added QALY falls far beyond what is usually considered to be cost effective. SMA screening does not approach the cost-effective range ($50-100,000/QALY) until the cost of severe disease is over $7 million or the cost of the mild disease is over $17 million, both of which are more than 20 times the baseline estimates. As such, we feel there is little chance that the basic finding that universal SMA testing is not cost effective would change appreciably with different model inputs."
The article is "The cost effectiveness of prenatal screening for spinal muscular atrophy " by Sarah E. Little, MD; Vanitha Janakiraman, MD; Anjali Kaimal, MD, MAS; Thomas Musci, MD; Jeffrey Ecker, MD; and Aaron B. Caughey, MD, PhD. It appears in the American Journal of Obstetrics & Gynecology , Volume 202, Issue 3 (March 2010) published by Elsevier.
Explore Related Topics
1 - How to Make a Baby Stop Crying Using Transport Response - Comparing the effects of the transport response, the relaxed reaction while being carried, with motionless maternal holding or rocking and examining if the effects persist with longer carrying in infants.
2 - Coaxing Kids Through Vaccinations: Pain Expectation is Pain Reality for Children - University of California Riverside researchers examine how expectation of pain influences pain experience in children.
3 - Types of Genetic Mutations Associated with Nephrotic Syndrome Identified - By analyzing most common genetic variants scientists aim at improving diagnosis and treatment for nephrotic syndrome which presents high resistance to drugs and relapse in post-transplant scenario.
4 - Siblings of Cot Death Victims Have Four Times SIDS Risk - Researchers calculated incidence of SIDS in younger siblings compared to the general population and found younger siblings of SIDS victims had four-fold increased risk of SIDS compared to the general population.
5 - Jaundice in the Newborn Baby - Jaundice is actually a symptom not a disease, it is recognized primarily by the yellow discoloration of the skin.
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): Elsevier Health Sciences. (2010, March 8). Prenatal Screening for Spinal Muscular Atrophy too Costly. Disabled World. Retrieved October 11, 2024 from www.disabled-world.com/health/pediatric/spinal-muscular-atrophy-screening.php
Permalink: <a href="https://www.disabled-world.com/health/pediatric/spinal-muscular-atrophy-screening.php">Prenatal Screening for Spinal Muscular Atrophy too Costly</a>: Is prenatal screening for rare diseases like spinal muscular atrophy too costly.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.